the aid library

LIST OPTIONS

Filter

4744

Coronavirus SARS-CoV-2/ COVID-19 Pandemic: Information and interim guidelines for pharmacists and the pharmacy workforce

International Pharmaceutical Federation (FIP) (2020) CC

The purpose of this document is to provide relevant information and guidelines on coronavirus outbreaks – and in particular the novel coronavirus SARS-CoV-2 and the diseases it produces, COVID-19 – for pharmacists and the pharmacy workforce, both in a primary care context (i.e. community phar... more

Download (142)

View PDF (208)

Climate change and health: vulnerability and adaptation assessment (Update)

World Health Organization WHO; PAHO; et al. (2021) C_WHO

In 2013 the World Health Organization (WHO) published the report Protecting health from climate change:vulnerability and adaptation assessment. The aim was to provide basic and flexible guidance on conducting national or subnational assessments of current and future vulnerability (the susceptibilit... more

Download (222)

View PDF (282)

WHO recommendations on maternal and newborn care for a positive postnatal experience
recommended

World Health Organization WHO (2022) CC

This guideline aims to improve the quality of essential, routine postnatal care for women and newborns with the ultimate goal of improving maternal and newborn health and well-being. It recognizes a “positive postnatal experience” as a significant end point for all women giving birth and their n... more

External Link

Future of Nursing 2020-2030

Wakefield, M.K.; et al. National Academy of Medicine; National Academies of Sciences, Engineering, and Medicine (2021) C1

Charting a Path to Achieve Health Equity. The decade ahead will test the nation's nearly 4 million nurses in new and complex ways. Nurses live and work at the intersection of health, education, and communities. Nurses work in a wide array of settings and practice at a range of professional levels. T... more

WHO recommendations on induction of labour, at or beyond term

World Health Organization WHO (2022) C_WHO

The primary audience for these recommendations includes health professionals who are responsible for developing national and local health-care guidelines and protocols and health workers involved in the provision of care to women and their newborns during pregnancy, labour and childbirth; this inclu... more

Download (200)

View PDF (262)

Global spending on health: rising to the pandemic’s challenges

World Health Organization WHO (2022) C_WHO

The results of the report clearly show that in 2020, a year dominated by the emergence of COVID-19 and its associated health and economic crises, governments around the world rose to the challenge. Sharp increases in government spending on health at all country income levels underpinned the rise in ... more

Download (113)

View PDF (168)

Operational manual on leishmaniasis vector control, surveillance, monitoring and evaluation

World Health Organisation (WHO) (2023) C_WHO

Despite the significant role of vector control in national leishmaniasis control programmes, the programmatic community perceives vector control as the weakest component of leishmaniasis control strategies in terms of resources, scientific evidence of the usefulness of interventions and capacity for... more

Download (167)

View PDF (204)

Treatment of Leprosy

Lockwod DN. The International Textbook of Leprosy (2018) CC

This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is a key component of leprosy treatment, as it is vital to prevent the progression of the infection. Treatment with rifampin and other antibiotics is highly effective and cures 98% of patients with the ... more

Download (119)

View PDF (142)

Clinical management of COVID-19: living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

As of 12 December 2022, over 645 million people worldwide have been diagnosed with COVID-19, with over 6.6 million deaths (4). The Omicron variant, which emerged in late November 2021, and its subvariants, are now the dominant circulating viruses, contributing to the ongoing surge in several countr... more

Download (163)

View PDF (184)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171 countries across all six WHO Regions and was rapidly re... more

Download (165)

View PDF (199)

Health needs assessment of the adult population in Ukraine: survey report September 2022

World Health Organisation WHO (2023) C_WHO

The full-scale invasion of Ukraine has caused a deterioration in the level of access to health-care services and medicines in the country, particularly for people living in regions close to the front line and areas that are not partially or fully controlled by the Government of Ukraine, and for peop... more

From emergency response to long-term COVID-19 disease management - Ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: Guidance on calibrating the r

World Health Organization WHO (2023) C_WHO

The key actions, activities, and approaches in this document are organized within each of the 5Cs (see Table 1 in the PDF) and those of the Strategic preparedness and response plan (SPRP) pillars as follows: National action plan key activities, prioritized for the current context and the current ... more

Download (245)

View PDF (343)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (213)

View PDF (285)

Leveraging the Learning Insights from HIV Programming for Pregnant and Parenting Adolescent Girls

UN Children's Fund UNICEF (2023) CC

Pregnancy and childbirth during adolescence profoundly affects the lives of millions of girls worldwide, and is a leading cause of maternal mortality and morbidity, and infant and child mortality. Every year, an estimated 21 million girls aged 15–19 years old in low- and middle-income countries be... more

External Link

World Heart Federation Roadmap for Heart Failure

Ferreira, J.P.; Kraus, S.; Mitchell, S. et al. Global Heart (2019) CC

In 2012, all Member States of the World Health Organization (WHO) endorsed a historical target to reduce premature mortality from noncommunicable diseases (NCD). This commitment was echoed in 2015 by the United Nations Sustainable Development Goals, which included a target to reduce premature morta... more

External Link

Management of a cholera epidemic - Practical guide for doctors, nurses, laboratory technicians, medical auxiliaries, water and sanitation specialists and logisticians
recommended

Médecins Sans Frontières MFS (2023) CC

Cholera is a transmissible diarrhoeal infection caused by Vibrio cholerae. Endemic and/or epidemic in over 40 countries (mainly in Africa and Asia), cholera continues to be a major global public health issue. The World Health Organization (WHO) estimates that the number of cases reported worldwid...e represents in reality only 5 to 10% of actual cases. This guide is intended for medical and non-medical staff responding to a cholera outbreak. It attempts to provide concrete answers to the questions and problems faced by staff, based on the recommendations of reference organisations, such as WHO and UNICEF, as well as Médecins Sans Frontières’ experience in the field. It is divided into 8 chapters. Chapter 1, Cholera overview, outlines the epidemiological and clinical features of cholera. Chapter 2, Outbreak investigation, explains the method and stages of a field investigation, from the alert to implementation of initial activities. Chapter 3, Cholera control measures, details measures and tools to prevent and/or control cholera transmission and mortality in populations affected, or at risk of being affected, by an epidemic (curative care, prevention means and health promotion activities). Chapter 4, Strategies for epidemic response, addresses the roll-out strategies of the measures described in Chapter 3 which depend on context (e.g. urban, rural, endemic, non-endemic setting, etc.), resources and particular constraints. Chapter 5, Cholera case management, details the different stages of cholera treatment, from diagnosis through to cure. Chapter 6, Setting up cholera treatment facilities, focuses on the installation of treatment facilities that vary in size and complexity according to operational requirements (treatment centres and units and oral rehydration points). Chapter 7, Organisation of cholera treatment facilities, describes the organisation of these specialized facilities in terms of human resources, supply, water, hygiene and sanitation, etc. Chapter 8, Monitoring and evaluation, presents the key data to be collected and analysed during an epidemic to facilitate a tailored response and evaluate its quality and effectiveness. The guide includes various practical tools in the appendices to facilitate activities (e.g. water quality tests, job descriptions, documents, etc.). Moreover, the toolbox also contains additional tools in editable formats (individual patient file, cholera case register, pictograms). Despite all efforts, it is possible that certain errors may have been overlooked in this guide. Please inform the authors of any errors detected. To ensure that this guide continues to evolve while remaining adapted to field realities, please send any comments or suggestions. more

Sharing successful strategies from the Eastern Mediterranean Region in mitigating noncommunicable diseases and mentalhealth disorders during the COVID-19pandemic and beyond

World Health Organization (WHO) Regional Office for the Eastern Mediterranean World Health Organization (WHO) Regional Office for the Eastern Mediterranean (2023) C_WHO

The "Stories from the field" document by the WHO Regional Office for the Eastern Mediterranean shares effective strategies from the Eastern Mediterranean Region for addressing noncommunicable diseases (NCDs) and mental health challenges, particularly during the COVID-19 pandemic. It highlights regio... more

The Global Asthma Report 2022

Global Asthma Network (2022) CC2

The Global Asthma Report (GAR) 2022, prepared by the Global Asthma Network (GAN), is the fourth such report (others 2011, 2014, 2018). GAN builds upon the work of the International Study of Asthma and Allergies in Childhood (ISAAC) and The International Union Against Tuberculosis and Lung Disease (T... more

Preventing HIV misdiagnosis: implementation guide

World Health Organization WHO (2024) CC

HIV testing programmes need to ensure that all clients who test for HIV are provided with correct diagnoses. The accuracy of HIV testing is critical to prevent misdiagnosis, as the consequences of giving an incorrect test result can be serious for clients, HIV testing services, HIV programmes and pu... more

WHO recommendations on maternal and newborn care for a positive postnatal experience recommended

Management of a cholera epidemic - Practical guide for doctors, nurses, laboratory technicians, medical auxiliaries, water and sanitation specialists and logisticians recommended

WHO recommendations on maternal and newborn care for a positive postnatal experience
recommended

Management of a cholera epidemic - Practical guide for doctors, nurses, laboratory technicians, medical auxiliaries, water and sanitation specialists and logisticians
recommended